EWTX (Edgewise Therapeutics) Other Financing: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EWTX Edgewise Therapeutics Inc EWTX
28 GF Score
Price $41.94
! 3 Warning Signs
View Full Analysis

What is Edgewise Therapeutics Other Financing?

Edgewise Therapeutics EWTX -0.10% 28 Other Financing is $0.00 Mil as of Jun. 2026. GuruFocus rates EWTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Edgewise Therapeutics's Other Financing for the three months ended in Jun. 2026 was $0.00 Mil.

Edgewise Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Edgewise Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Edgewise Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edgewise Therapeutics Other Financing Chart

Edgewise Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.24 0.47 0.55 10.11 8.73

Edgewise Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
EWTX
28GF Score
Edgewise Therapeutics Inc EWTX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edgewise Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
Edgewise Therapeutics (EWTX) has a Other Financing of $0.00 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Edgewise Therapeutics and its competitors.
Is Edgewise Therapeutics' Other Financing too high?
Edgewise Therapeutics' current Other Financing is $0.00 Mil. Overall, Edgewise Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Edgewise Therapeutics' Other Financing compare to DYN and PBLS?
Edgewise Therapeutics' Other Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Edgewise Therapeutics and its competitors. Edgewise Therapeutics's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edgewise Therapeutics stock overvalued right now?
Edgewise Therapeutics (EWTX) has a current Other Financing of $0.00 Mil. The current Other Financing is $0.00 Mil. Edgewise Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Edgewise Therapeutics (EWTX), the current Other Financing is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edgewise Therapeutics Business Description

Address 1715 38th Street, Boulder, CO, USA, 80301
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
28GF Score

Get the complete analysis for EWTX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.94
Price